TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.

I'm a paid subscriber please
log me in

I want to purchase this article for
only 99¢
(requires login)

I want to purchase five articles for
only $3.99
(requires login)

I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

Click here if you are an MIT alum and do not have access to this article.

June 2003

Cloning, Stem Cells, and Medicine's Future

Geron CEO Thomas B. Okarma on creating stem cell therapies.

By Erika Jonietz

Thomas B. Okarma

Position: President and CEO, Geron

Issue: Embryonic-stem-cell and cloning research. The U.S. political climate is proving inhospitable to biomedical research that could benefit millions, and other nations are jumping in to fill the void.

Personal Point of Impact: Over 20 years of research to create commercial cell-based therapies.

Select from the choices above
to read the entire article.

Customer Service

Magazine Services

•	Subscription FAQ
•	Pay Your Bill
•	Renew Your Subscription
•	Change Your Address
•	Check Your Start/Expire Issue
•	Feedback
•	Buy a Back Issue
•	Permissions/Reprints
•	Cancel Your Subscription
•	Digital Subscription Customer Service